READING, England British drug maker Archimedes Pharma plans to set up its U.S. headquarters in New Jersey, the company said.
The company said the New Jersey Economic Development Authority awarded it a grant to create up to 75 new jobs with its new headquarters, in the town of Bedminster. The company applied with the Food and Drug Administration for approval of PecFent (fentanyl), a nasal spray for treating breakthrough cancer pain, last August.
“The new U.S. headquarters in Bedminster is a significant milestone in Archimedes’ development as an emerging global specialty pharmaceutical company,” Archimedes president and CEO Jeffrey Buchalter said in a statement. “With Archimedes’ rapidly growing and diverse drug delivery technologies and products portfolio, we are in the process of establishing our own U.S. organization and are actively recruiting top-tier senior-level management positions to support market penetration across the U.S.A. and globally.”